Original Article
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 28, 2014; 20(48): 18207-18215
Published online Dec 28, 2014. doi: 10.3748/wjg.v20.i48.18207
Figure 5
Figure 5 Proteasome inhibition by bortezomib treatment inhibits chymotrypsin-like activity. A: Chymotrypsin-like activity; B: Trypsin-like activity. Values are mean ± SE. aP < 0.05 vs control. TNBS: 2,4,6-trinitrobenzene sulfonic acid; BTZ: Bortezomib.